Brivaracetam NDC 0121-1074

NDC codes

FDA NDC Directory

Product NDC (as listed)0121-1074Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00121-1074Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0121-1074-10	00121107410	1 BOTTLE in 1 CARTON (0121-1074-10) / 300 mL in 1 BOTTLEMarketed from Feb 23, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Brivaracetam
Generic name (nonproprietary): brivaracetam
Active ingredients: Brivaracetam — 10 mg/mL
Dosage form: Solution
Route: Oral
Labeler: PAI Holdings, LLC dba PAI Pharma
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218494
Marketing start: Feb 23, 2026
Listing expires: Dec 31, 2027
DEA schedule: CV
Other FDA classes: Epoxide Hydrolase Inhibitors (Mechanism)
Identifiers: Product ID 0121-1074_6e474aba-29da-4afb-801c-000ca4393f74SPL ID 6e474aba-29da-4afb-801c-000ca4393f74SPL set ID 57627ea9-3b14-4428-ad95-6ea25ecaef31RxCUI 1739785UNII U863JGG2IA

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400121107410 followed by a unit qualifier and the quantity

Package 00121-1074-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 3, 2026.

Indications (excerpt from the label)

Brivaracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Brivaracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218494

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218494
Product	Strength	Form · route	Labeler	Product NDC
brivaracetam	Brivaracetam 10 mg/mL	SolutionOral	Zhejiang Poly Pharm. Co., Ltd.	72673-031